Yalaz Ceren, Bridges Esther, Alham Nasullah K, Zois Christos E, Chen Jianzhou, Bensaad Karim, Miar Ana, Pires Elisabete, Muschel Ruth J, McCullagh James S O, Harris Adrian L
Molecular Oncology Laboratories, Department of Medical Oncology, John Radcliffe Hospital, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, OX3 9DS, UK.
Department of Engineering Science, Institute of Biomedical Engineering (IBME), University of Oxford, Old Road Campus Research Building, Oxford, OX3 7DQ, UK.
Cancer Metab. 2024 Feb 13;12(1):5. doi: 10.1186/s40170-023-00326-y.
PDE6H encodes PDE6γ', the inhibitory subunit of the cGMP-specific phosphodiesterase 6 in cone photoreceptors. Inhibition of PDE6, which has been widely studied for its role in light transduction, increases cGMP levels. The purpose of this study is to characterise the role of PDE6H in cancer cell growth.
From an siRNA screen for 487 genes involved in metabolism, PDE6H was identified as a controller of cell cycle progression in HCT116 cells. Role of PDE6H in cancer cell growth and metabolism was studied through the effects of its depletion on levels of cell cycle controllers, mTOR effectors, metabolite levels, and metabolic energy assays. Effect of PDE6H deletion on tumour growth was also studied in a xenograft model.
PDE6H knockout resulted in an increase of intracellular cGMP levels, as well as changes to the levels of nucleotides and key energy metabolism intermediates. PDE6H knockdown induced G1 cell cycle arrest and cell death and reduced mTORC1 signalling in cancer cell lines. Both knockdown and knockout of PDE6H resulted in the suppression of mitochondrial function. HCT116 xenografts revealed that PDE6H deletion, as well as treatment with the PDE5/6 inhibitor sildenafil, slowed down tumour growth and improved survival, while sildenafil treatment did not have an additive effect on slowing the growth of PDE6γ'-deficient tumours.
Our results indicate that the changes in cGMP and purine pools, as well as mitochondrial function which is observed upon PDE6γ' depletion, are independent of the PKG pathway. We show that in HCT116, PDE6H deletion replicates many effects of the dark retina response and identify PDE6H as a new target in preventing cancer cell proliferation and tumour growth.
PDE6H编码PDE6γ',即视锥光感受器中cGMP特异性磷酸二酯酶6的抑制亚基。磷酸二酯酶6(PDE6)在光转导中的作用已得到广泛研究,抑制该酶可提高cGMP水平。本研究旨在表征PDE6H在癌细胞生长中的作用。
通过对487个参与代谢的基因进行siRNA筛选,PDE6H被确定为HCT116细胞中细胞周期进程的调控因子。通过检测PDE6H缺失对细胞周期调控因子水平、mTOR效应因子、代谢物水平和代谢能量测定的影响,研究了PDE6H在癌细胞生长和代谢中的作用。还在异种移植模型中研究了PDE6H缺失对肿瘤生长的影响。
PDE6H基因敲除导致细胞内cGMP水平升高,以及核苷酸和关键能量代谢中间体水平的变化。PDE6H基因敲低诱导癌细胞系中G1期细胞周期停滞和细胞死亡,并降低mTORC1信号传导。PDE6H的基因敲低和基因敲除均导致线粒体功能受到抑制。HCT116异种移植实验表明,PDE6H缺失以及使用PDE5/6抑制剂西地那非治疗均可减缓肿瘤生长并提高生存率,而西地那非治疗对减缓PDE6γ'缺陷型肿瘤的生长没有叠加作用。
我们的结果表明,PDE6γ'缺失时观察到的cGMP和嘌呤池变化以及线粒体功能变化与PKG途径无关。我们发现,在HCT116细胞中,PDE6H缺失可重现许多暗视网膜反应的效应,并确定PDE6H是预防癌细胞增殖和肿瘤生长的新靶点。